Suspensions of AstraZeneca vaccine rollout over side-effect fears will fuel global vaccine hesitancy

Predictions

  • Suspensions of AstraZeneca vaccine rollout over side-effect fears will fuel global vaccine hesitancy despite swift resumption of use
  • Reduced confidence in AstraZeneca will risk diminishing demand in EU, raising risk of insufficient protection to prevent further waves next winter
  • AstraZeneca’s role in COVAX means suspensions will undermine demand globally, potentially prolonging pandemic in poorer countries

Event

Denmark, Norway and Iceland announced on 11 March they would suspend use of the Oxford/AstraZeneca ChAdOx-1 coronavirus (COVID-19) vaccine, citing concerns over side-effects, specifically blood clotting disorders. 

Falanx Assynt is a global intelligence consultancy and leading provider of geopolitical, strategic and business risk analysis since 2003. Falanx Assynt is part of Falanx Group Ltd (LON:FLX) which, through its subsidiaries, provides cyber defence and intelligence services to blue chip and government clients worldwide.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Falanx Group Ltd

More articles like this